Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04682145 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Feb 1, 2026 → Dec 1, 2026
See other at-risk trials from Novo Nordisk

Record History

  1. Primary and study completion pushed from Feb 1, 2026 to Dec 1, 2026 Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S · Secondary endpoints: details revised at 1 of 1 entry · Eligibility criteria expanded, about 2 words Show 3 more changesShow less
    • Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S
    • Secondary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 2 words
  2. Primary and study completion dates: Apr 1, 2025 to Feb 1, 2026v5
  3. 3 versions Re-verified since Jan 18, 2022, no change to tracked fieldsv2-v4
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Hemophilia
236 trials monitored
See 12 trials at risk
This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.
Trial Details
NCT Number NCT04682145
Lead Sponsor Novo Nordisk A/S
Conditions Haemophilia A
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov